| abstract |
New bicyclic compounds of the general formula (I), <IMAGE> (I) wherein R1 and R2 each represent a C1-6 alkyl group, and R3 is an etherified hydroxy group of the formula -CR4, wherein R4 is benzyl group, benzhydryl group or a phenyl group bearing optionally a phenyl or a trihalomethyl substituent or one or more halogen substituent(s), or R3 is an esterified hydroxy group of the formula -OCO-R5, which represents a phenyl-(C1-5 alkyl)-carbonyloxy group, a cinnamoyloxy group having optionally a halogen or one or more C1-4 alkoxy substituent(s), a benzoyloxy group having optionally a C1-4 alkyl, phenyl or trihalomethyl substituent or one or more C1-4 alkoxy substituent(s), one or more halo substituent(s) and/or nitro substituent, a benzyloyloxy group, a xanthene-9-carbonyloxy group, an optionally substituted naphthoyloxy group, or an acyloxy group derived from a five- or six-membered heterocyclic carboxylic acid bearing optionally a halo substituent on the ring, are prepared by etherifying or esterifying a bicyclic compound of the general formula (II), <IMAGE> (II) wherein R1 and R2 are as defined above. The new compounds according to the invention possess anti-arrhythmic effects and can be applied to advantage in the therapy of cardiac rhythm disorders. |